BFM
LGND icon

Boothbay Fund Management’s Ligand Pharmaceuticals LGND Stock Holding History

Boothbay Fund Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-242
Closed -$1.1M – 1051
2020
Q1 		$1.1M Buy
+242
New +$13.7K 0.09% 280

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Boothbay Fund Management's LGND Position: Q4 2021 in Review

Boothbay Fund Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2021, closing a stake of 30,362 shares — an estimated $2.64M sold.

Boothbay Fund Management first reported a position in LGND in Q1 2019 and held it in 4 quarters. The position peaked at $3.6M in Q2 2021. 221 funds tracked by Wall St. Rank hold LGND as of Q4 2021.

  • Boothbay Fund Management reported no remaining Ligand Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 30,362 Ligand Pharmaceuticals shares in Q4 2021, an estimated $2.64M.
  • Boothbay Fund Management first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Boothbay Fund Management's Ligand Pharmaceuticals position peaked at $3.6M in Q2 2021.
  • 221 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.